Literature DB >> 24375387

Relationship between histologic response and the degree of tumor shrinkage after chemoradiotherapy in patients with locally advanced rectal cancer.

Toshiyuki Suzuki1, Sotaro Sadahiro, Akira Tanaka, Kazutake Okada, Gota Saito, Akemi Kamijo, Takeshi Akiba, Shuichi Kawada.   

Abstract

BACKGROUND: Preoperative chemoradiotherapy (CRT) significantly decreases local recurrence in advanced rectal cancer. We studied whether the degree of tumor shrinkage can be used as a predictor of histologic response.
METHODS: The subjects were 114 patients with locally advanced rectal cancer who underwent total mesorectal excision after receiving radiotherapy combined with uracil/tegafur (UFT) or S-1. The degree of tumor shrinkage based on barium enema examination and magnetic resonance imaging (MRI) were assessed before CRT and immediately before surgery.
RESULTS: A histologic complete response (ypCR), histologic marked regression, T and N downstaging were associated with significantly higher tumor-shrinkage rates on barium enema (P < 0.01, P < 0.01, P < 0.01, and P < 0.01, respectively) as well as on MRI (P < 0.01, P < 0.01, P < 0.01, and P = 0.01, respectively). On multivariate analysis, ypCR and histologic marked regression were significantly related only to tumor-shrinkage rates on barium enema (P < 0.01 and P < 0.01, respectively), and were not related to tumor-shrinkage rates on MRI.
CONCLUSIONS: The degree of tumor shrinkage is closely related to the final histologic response. Two-dimensionally evaluated tumor-shrinkage rates based on barium enema are adequate for the prediction of histologic response.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemoradiotherapy; histologic regression; rectal cancer; tumor shrinkage

Mesh:

Year:  2013        PMID: 24375387     DOI: 10.1002/jso.23550

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Relations of Changes in Serum Carcinoembryonic Antigen Levels before and after Neoadjuvant Chemoradiotherapy and after Surgery to Histologic Response and Outcomes in Patients with Locally Advanced Rectal Cancer.

Authors:  Gota Saito; Sotaro Sadahiro; Takashi Ogimi; Hiroshi Miyakita; Kazutake Okada; Akira Tanaka; Toshiyuki Suzuki
Journal:  Oncology       Date:  2017-12-22       Impact factor: 2.935

2.  Predictors and histological effects of preoperative chemoradiotherapy for rectal cancer and control of lateral lymph node metastasis.

Authors:  Hiroshi Miyakita; Lin Fung Chan; Kazutake Okada; Hajime Kayano; Masaki Mori; Sotaro Sadahiro; Seiichiro Yamamoto
Journal:  BMC Gastroenterol       Date:  2022-07-08       Impact factor: 2.847

3.  Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.

Authors:  Sotaro Sadahiro; T Suzuki; A Tanaka; K Okada; G Saito; H Miyakita; T Ogimi; H Nagase
Journal:  Cancer Chemother Pharmacol       Date:  2017-04-17       Impact factor: 3.333

4.  Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer.

Authors:  Zheng-Yan Li; Xiao-Dong Wang; Mou Li; Xi-Jiao Liu; Zheng Ye; Bin Song; Fang Yuan; Yuan Yuan; Chun-Chao Xia; Xin Zhang; Qian Li
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

5.  Commentary on neoadjuvant therapy followed by local excision and two-stage total mesorectal excision: a new strategy for sphincter preservation in locally advanced ultra-low rectal cancer.

Authors:  Andrew P Zbar
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-05

6.  Mucinous components assessed by magnetic resonance imaging in primary rectal cancer tissue before and after chemoradiotherapy and tumor response.

Authors:  Hiroshi Miyakita; Sotaro Sadahiro; Takashi Ogimi; Gota Saito; Kazutake Okada; Akira Tanaka; Toshiyuki Suzuki; Hiroshi Kajiwara; Hiroshi Yamamuro; Takeshi Akiba
Journal:  Int J Colorectal Dis       Date:  2018-04-26       Impact factor: 2.571

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.